Ipilimumab-Induced Hypophysitis: MR Imaging Findings

References

1. 1.↵
   1. Keilholz U

   . CTLA-4: Negative regulator of the immune response and a target for cancer therapy. J Immunother 2008;31:431–39

   CrossRefPubMed
2. 2.↵
   1. Weber J

   . Review: anti-CTLA-4 antibody ipilimubab—case studies of clinical response and immune-related adverse events. Oncologist 2007;12:864–72

   Abstract/FREE Full Text
3. 3.↵
   1. Cranmer LD,
   2. Hersh E

   . The role of CTLA4 blockade in the treatment of malignant melanoma. Cancer Invest 2007;25:613–31

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Cheung CC,
   2. Ezzat S,
   3. Smyth HS,
   4. et al

   . The spectrum and significance of primary hypophysitis. J Clin Endocrinol Metab 2001;86:1048–53

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Sautner D,
   2. Saeger W,
   3. Ludecke DK,
   4. et al

   . Hypophysitis in surgical and autoptical specimens. Acta Neuropathol 1995;90:637–44

   PubMed
6. 6.↵
   1. Swearingen B,
   2. Biller BM

   . Diagnosis and Management of Pituitary Disorders. Totowa, NJ: Humana Press; 2008
7. 7.↵
   1. Ahmadi J,
   2. Meyers GS,
   3. Segall HD,
   4. et al

   . Lymphocytic adenohypophysitis: contrast-enhanced MR imaging in five cases. Radiology 1995;195:30–34

   PubMed
8. 8.↵
   1. Sato N,
   2. Sze G,
   3. Endo K

   . Hypophysitis: endocrinologic and dynamic MR findings. AJNR Am J Neuroradiol 1998;19:439–44

   Abstract
9. 9.↵
   1. Sato N,
   2. Ishizaka H,
   3. Yagi H,
   4. et al

   . Posterior lobe of the pituitary in diabetes insipidus: dynamic MR imaging. Radiology 1993;186:357–60

   PubMedWeb of Science
10. 10.↵
    1. Maghnie M,
    2. Genovese E,
    3. Arico M,
    4. et al

    . Evolving pituitary hormone deficiency is associated with pituitary vasculopathy: dynamic MR study in children with hypopituitarism, diabetes insipidus, and Langerhans cell histiocytosis. Radiology 1994;193:493–99

    PubMedWeb of Science